Verily Launches Landmark Partnership With CU Anschutz And UCHealth [Forbes]
Celldex Therapeutics, Inc. (CLDX)
Last celldex therapeutics, inc. earnings: 11/12 08:01 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.celldex.com
Company Research
Source: Forbes
entailing research ready biomedical pipelines and datasets. In addition, the partnership is aiming to build curated AI models across a variety of specific therapeutic and drug areas, such as oncology, musculoskeletal and transplant medicine, to name a few. All of this work will be done using CU Anschutz's vast research datasets via Verily Workbench, one of the company's flagship products. Workbench is a secure research environment which enables deep analytics for multimodal biomedical data. Importantly, the platform enables researchers to dial into varying degrees of computational analytics, bring structure to multimodal datasets that are otherwise not conducive to insight generation, and most importantly, does all of this with a strong, safe, secure and compliant infrastructure. RefinedScience is a joint venture between CU Anschutz and UCHealth that will use this technology to bring multiomic datasets together to generate actionable insights. The vision for the group is to produc
Show less
Read more
Impact Snapshot
Event Time:
CLDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLDX alerts
High impacting Celldex Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CLDX
News
- Celldex Therapeutics (NASDAQ:CLDX) had its price target lowered by analysts at Barclays PLC from $25.00 to $21.00. They now have an "underweight" rating on the stock.MarketBeat
- Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
- Celldex Announces Appointment of Teri Lawver as Chief Commercial OfficerGlobeNewswire
- Celldex to Present at Upcoming Investor ConferencesGlobeNewswire
- Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) StudyGlobeNewswire
CLDX
Earnings
- 11/10/25 - Miss
CLDX
Sec Filings
- 12/4/25 - Form 144
- 11/17/25 - Form 4
- 11/14/25 - Form SCHEDULE
- CLDX's page on the SEC website